Squadron Capital Management LLC
OAK BROOK, IL · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$337.4M2026 Q3+ $61.0M options (notional, not included)
Positions45
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.56.6%
What Changed This Quarter?
Top Holdings
KOD
Kodiak Sciences
10.0%
CCCC
C4 Therapeutics
7.8%
COGT
Cogent Biosciences
7.4%
KODCALL
Kodiak Sciences
6.4%
SLN
Silence Therapeutics
5.7%
ZNTL
Zentalis Pharmaceuticals
4.7%
EWTX
Edgewise Therapeutics
4.3%
RLAY
Relay Therapeutics
3.6%
New / Increased
21 new · 11 increased
KODCALLNEW
Kodiak Sciences
6.4%
SLNNEW
Silence Therapeutics
5.7%
ORICNEW
Oric Pharmaceuticals
3.4%
PHVSNEW
N.V. Pharvaris
3.2%
VERANEW
Vera Therapeutics
2.5%
DFTX
Definium Therapeutics
3.2%
+300.0%
ZNTL
Zentalis Pharmaceuticals
4.7%
+84.5%
CCCC
C4 Therapeutics
7.8%
+29.4%
Reduced / Exited
8 reduced · 19 sold out
RLMD
Relmada Therapeutics
3.3%
-52.4%
KOD
Kodiak Sciences
10.0%
-16.0%
RLAY
Relay Therapeutics
3.6%
-19.1%
IKT
Inhibikase Therapeutics
1.0%
-33.3%
AVBPCALL
Arrivent Biopharma
1.1%
-22.1%
MAZEEXIT
Maze Therapeutics
3.1%
ELVNEXIT
Enliven Therapeutics
2.5%
FBRXGBPEXIT
Forte Biosciences
1.5%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.